What Гофен 400 Treats: Main Uses and Benefits

Гофен 400 (Ibuprofen 400 mg) provides targeted symptomatic relief across key therapeutic domains characterized by symptoms related to physical discomfort, inflammatory states, and systemic imbalance. This medication supports patients during episodes of heightened discomfort. Ibuprofen is relevant for easing mild to moderate pain, including symptoms associated with headaches, dental procedures, muscle aches, and painful menstrual cycles.

---

Key Therapeutic Domains

This medication is commonly used to address groups of symptoms that may appear suddenly or intensify over time, providing support in scenarios where additional management of discomfort is required. It is applied across therapeutic domains involving inflammatory or irritative states and is relevant in contexts involving systemic imbalance.

Mini-Quote:

“Applied in scenarios where additional management of discomfort is required, this medication contributes to improved comfort during periods of heightened symptoms.”

---

Easing Discomfort and Supporting Function

Гофен 400 supports patients by simultaneously addressing the core cluster of symptoms: pain, inflammation, and fever. This supports patients during episodes of heightened discomfort by easing distress and addressing symptoms of increased neurological or muscular activity. This can assist with maintaining functional stability when symptoms interfere with routine activities, such as managing pain and swelling from a strain or sprain, or easing the discomfort of an acute cold or flu episode.

Quick Fact: Relief for Pain, Inflammation, and Fever

The medicine is commonly used across conditions presenting with acute episodes to ease symptoms that create noticeable physiological strain.

Regulatory References

1. NIH MedlinePlus overview

Гофен 400 (Ibuprofen 400 mg) is officially eligible for use by Adults and Adolescents 12 years of age for short-term symptomatic relief. However, regulatory guidelines establish several absolute restrictions and conditional limitations based on pre-existing health status and patient population.

---

Contraindicated Populations (Must Not Use)

Use is strictly prohibited for patients with a known hypersensitivity to Ibuprofen, aspirin, or any other NSAID. Absolute contraindications also apply to those with active or recurrent peptic ulcers, gastrointestinal bleeding, or 2 distinct episodes of haemorrhage. The medication must not be used by patients with severe heart failure (NYHA Class IV), severe renal failure, severe hepatic failure, or following Coronary Artery Bypass Graft (CABG) surgery.

---

Age- and Condition-Based Restrictions

• Children: The 400 mg strength is not recommended for children under 12 years of age.
• Older Adults (Geriatric): Use requires special caution; the lowest effective dose should be used for the shortest duration due to an increased risk of serious adverse reactions.
• Conditional Use: Caution is required for patients with mild to moderate organ impairment (hepatic or renal), uncontrolled hypertension, mild to moderate heart failure, or established cardiovascular disease.

---

Pregnancy and Fertility Status

The medicine is formally contraindicated during the last trimester of pregnancy (from 30 weeks gestation). Use is also generally not recommended from 20 weeks of gestation due to potential risks to the fetus. Use is not recommended for women who are actively attempting to conceive due to possible impairment of female fertility.

Interactions with other medicines and products

This interaction profile for Гофен 400 (Ibuprofen) is structured by official regulatory documentation concerning pharmacodynamic and pharmacokinetic interactions.

Interaction Type & Class	Specific Interacting Agents (Regulatory Focus)
Pharmacodynamic Risk	Anticoagulants (Warfarin, Heparin), Antiplatelet agents, Corticosteroids, SSRIs
Renal Clearance Effect	Lithium, Methotrexate, Ciclosporin, Tacrolimus
Efficacy Reduction	Diuretics (Thiazides, Loop), Antihypertensives (ACE inhibitors, ARBs)

The co-administration of Гофен 400 is contraindicated with other nonsteroidal anti-inflammatory drugs (NSAIDs) and high-dose aspirin to prevent an increased risk of serious gastrointestinal ulceration or bleeding. It is also officially contraindicated in the setting of coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy.

Regarding pharmacokinetic interactions, Гофен 400 may reduce the renal clearance of agents such as Lithium and Methotrexate, which can lead to increased plasma concentrations of the co-administered drug, a finding explicitly noted in regulatory sources. Furthermore, use with Diuretics and Antihypertensives may reduce the therapeutic efficacy of those medicines, potentially leading to deterioration of renal function, particularly in elderly or volume-depleted patients. Concomitant use with daily alcohol consumption is associated with an augmented risk of gastrointestinal bleeding.

Гофен 400 contains the active compound ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) administered as a racemic mixture. Its primary mechanism of action is the non-selective, competitive, and reversible inhibition of the cyclooxygenase (COX) enzymes, specifically COX-1 (prostaglandin G/H synthase 1, PTGS1) and COX-2 (prostaglandin G/H synthase 2, PTGS2).

These enzymes catalyze the conversion of arachidonic acid, a fatty acid precursor released from cell membranes, into unstable prostaglandin H2 ( PGH2). This interruption blocks the committed step in the synthesis of prostanoids, including prostaglandins ( PGE2, PGF2alpha, PGD2), prostacyclin ( PGI2), and thromboxane A2 ( TxA2).

The intracellular consequence is a reduced concentration of prostanoids in targeted tissues. System-level physiological modulation occurs through the downstream effects of decreased prostanoid signaling. Specifically, the reduction in PGE2 synthesis within the hypothalamus affects thermoregulation, and the decreased levels of prostanoids, such as PGE2 and PGI2, modulate vascular permeability, leukocyte chemotaxis, and the sensitization threshold of peripheral nociceptors. The inhibition of platelet COX-1 leads to a transient, reversible suppression of TxA2 production, which affects platelet aggregation.

Official Administration Guidelines

Instruction	Regulatory Detail
Route of Administration	Oral (via capsule or tablet).
Standard Dosing	Standard dose is 400 mg.
Maximum Daily Dose	Non-prescription use is limited to 1200 mg in a 24-hour period. Higher doses (up to 3200 mg) are reserved for supervised prescription use.
Frequency Pattern	Doses may be repeated every 4 to 6 hours as required for symptoms, provided the maximum daily intake is not exceeded.
Timing & Handling	The dose may be taken with food or milk to help reduce potential gastrointestinal discomfort. The capsule/tablet must be swallowed whole with water.
Duration of Use	Self-treatment is limited to a maximum of 10 days for pain and 3 days for fever. Use beyond these limits requires continuous medical oversight.
Population Rule	The general principle for older adults is to use the lowest effective dose for the shortest duration.

---

Procedural Summary

The official use protocol is structured around a precise procedural sequence. Administration involves swallowing the specific dose orally with water, ensuring that a minimum of four hours passes between doses. The primary regulatory constraint requires strict adherence to the stated maximum daily dose and the established short-term duration limits for self-medication. If a dose is missed, the next dose should be taken at the next scheduled time, and doubling the dose is not permitted. This procedural structure is designed to guide the standardized use of the medication.

Research Evidence / Overview of Studies for Гофен 400

Гофен 400 (Ibuprofen) was studied for its role in exploring common acute symptoms. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate its effects under specific, controlled research conditions. Understanding this research involves looking at what was studied, what patterns were observed in some studies, and what questions still require further data.

---

Evidence for Use in Acute Pain Relief

Research has extensively examined the use of Гофен 400 for outcomes related to physical discomfort associated with acute or disruptive episodes. Numerous short-term RCTs compared Ibuprofen against placebo or other active agents, measuring patient-reported discomfort over time. Studies monitored patterns such as the typical time required for pain intensity measurements to evolve. However, long-term effects are not fully established for the typical over-the-counter use model, and follow-up durations were limited.

---

Evidence for Use in Fever Reduction

Research on Ibuprofen was evaluated in settings exploring outcomes related to fever. The studies, including RCTs and Meta-analyses, monitored outcomes related to how temperature evolved, examining the degree of measured temperature evolution and the proportion of individuals exhibiting specific temperature patterns at defined time intervals. Existing studies provide limited insight into the resolution of the accompanying symptoms of illness beyond the specific change in core body temperature.

---

Evidence in Specific Patient Groups

Research has specifically explored the use of Ibuprofen in certain patient cohorts, including the pediatric population (children) and adults. While studies were observed in older adult populations, data for certain groups remain insufficient. Evidence focused specifically on subgroups with complex comorbidities is often limited, meaning results apply only to the populations studied in the primary trials.

---

Long-Term Study Design and Durability

The majority of the research has focused on short-term, acute symptom management, resulting in limited information for long-term outcomes or the durability of the observed responses. Research into long-term patterns is typically addressed in separate, large-scale post-market observational studies, which examine different outcomes than the acute efficacy trials.

Key Studies & References Ibuprofen (Systemic) - NIH MedlinePlus

Common questions about Гофен 400 (FAQ)

Q: What is Гофен 400, and what is it used for?

Гофен 400 is a medication that contains Ibuprofen, which belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). It is a formulation that has been studied for its potential effects on the body's inflammatory response and for providing symptomatic relief from pain and fever. These effects are generally recognized in the context of mild to moderate pain, such as headaches or muscle aches, and reducing elevated body temperature. The active ingredient is Ibuprofen at a dose of 400 mg.

---

Q: How does Ibuprofen (the active ingredient in Гофен 400) work in the body?

The active ingredient, Ibuprofen, has been shown in research to exert its action by influencing the body’s production of prostaglandins. Prostaglandins are natural substances that can mediate pain, inflammation, and fever. Ibuprofen’s mechanism involves a temporary interference with the enzyme system responsible for creating these prostaglandins. This action is believed to be the primary basis for its reported anti-inflammatory, fever-reducing, and pain-relieving effects.

---

Q: Does taking Гофен 400 guarantee my pain will go away completely?

Research and clinical experience indicate that the active ingredient in Гофен 400, Ibuprofen, may help to alleviate symptoms of pain and inflammation in many people. However, no medication guarantees that pain will be entirely or instantly resolved. The actual level of symptom relief can vary depending on individual patient factors, the severity of the condition, and the underlying cause of the pain. It is essential to consult a healthcare professional to manage pain effectively, as this medication is not a substitute for professional medical evaluation.

---

Q: What should I know about taking Гофен 400 with other medications?

When considering Гофен 400 alongside other treatments, it is important to be aware of potential drug interactions. Because the active ingredient is an NSAID, there is a possibility of interactions with other medicines, especially those that affect blood clotting (like anticoagulants), blood pressure, or kidney function. Always inform your doctor or pharmacist about all other medications, supplements, or herbal products you are currently taking before starting Гофен 400. They can provide specific guidance based on your full medical profile.

---

Q: Is there a risk of side effects associated with Гофен 400?

As with most medications, Ibuprofen, the active component of Гофен 400, is associated with the potential for side effects. Common effects reported in studies may include mild digestive issues, such as nausea or stomach upset. Less common, but more serious, effects have involved the gastrointestinal tract (like ulcers or bleeding) and cardiovascular system. The risk of these effects is generally tied to factors like dosage, duration of use, and pre-existing medical conditions. A qualified healthcare provider can help assess the potential risks and benefits for your specific situation.

How to Store and Dispose of Gofen 400

The storage and disposal of Gofen 400 mg Soft Gel Capsules must strictly follow official regulatory requirements to ensure product stability and safety.

---

Required Storage Conditions

Item	Requirement (Based on Official Regulatory Documents)
Temperature	Store below 30°C (86°F).
Protection	Must be stored in a dry place and away from direct sunlight.
Child Safety	Mandatory to keep out of the sight and reach of children.
Stability	The official shelf life is 24 months when stored under these conditions.

---

Disposal Instructions

Official documents state there are no special requirements for the disposal of the unused medicinal product. Expired or unused Gofen 400 should be discarded in accordance with local municipal requirements, as it is not classified as hazardous waste requiring special handling streams.